Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway

  1. Núria de la Iglesia1,7,
  2. Genevieve Konopka1,2,7,
  3. Sidharth V. Puram1,3,
  4. Jennifer A. Chan4,
  5. Robert M. Bachoo5,
  6. Mingjian J. You5,
  7. David E. Levy6,
  8. Ronald A. DePinho5, and
  9. Azad Bonni1,2,3,8
  1. 1 Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115, USA;
  2. 2 Program in Neuroscience, Harvard Medical School, Boston, Massachusetts 02115, USA;
  3. 3 Program in Biological and Biomedical Sciences, Harvard Medical School, Boston, Massachusetts 02115, USA;
  4. 4 Division of Neuropathology, Department of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts 02115, USA;
  5. 5 Department of Medical Oncology, Center for Applied Cancer Science of the Belfer Institute for Innovative Cancer Science, Dana-Farber Cancer Institute, and Department of Medicine and Department Genetics, Harvard Medical School, Boston, Massachusetts 02115 USA;
  6. 6 Department of Pathology and Department of Microbiology, New York University School of Medicine, New York, New York 10016, USA
  1. 7 These authors contributed equally to this work.

Abstract

Activation of the transcription factor STAT3 is thought to potently promote oncogenesis in a variety of tissues, leading to intense efforts to develop STAT3 inhibitors for many tumors, including the highly malignant brain tumor glioblastoma. However, the function of STAT3 in glioblastoma pathogenesis has remained unknown. Here, we report that STAT3 plays a pro-oncogenic or tumor-suppressive role depending on the mutational profile of the tumor. Deficiency of the tumor suppressor PTEN triggers a cascade that inhibits STAT3 signaling in murine astrocytes and human glioblastoma tumors. Specifically, we forge a direct link between the PTEN–Akt–FOXO axis and the leukemia inhibitory factor receptor β (LIFRβ)–STAT3 signaling pathway. Accordingly, PTEN knockdown induces efficient malignant transformation of astrocytes upon knockout of the STAT3 gene. Remarkably, in contrast to the tumor-suppressive function of STAT3 in the PTEN pathway, STAT3 forms a complex with the oncoprotein epidermal growth factor receptor type III variant (EGFRvIII) in the nucleus and thereby mediates EGFRvIII-induced glial transformation. These findings indicate that STAT3 plays opposing roles in glial transformation depending on the genetic background of the tumor, providing the rationale for tailored therapeutic intervention in glioblastoma.

Keywords

Footnotes

| Table of Contents

Life Science Alliance